Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C
The company said it needs more time to verify manufacturing and quality-control data after five late-stage trials showed strong weight-loss results.
- On Thursday, July 23, 2026, Eli Lilly and Company announced plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027.
- Dubbed the 'triple G' drug, retatrutide targets GLP-1, GIP, and glucagon hormones, which Lilly believes offers more potent appetite effects than existing treatments.
- In the TRIUMPH-2 and TRIUMPH-3 trials, patients with obesity, diabetes, and cardiovascular disease lost up to an average of 22.6% of their body weight at 80 weeks.
- Lilly Executive Vice President Kenneth Custer said, "Across five positive Phase 3 studies, retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health."
- Before submitting the application, Lilly must verify manufacturing and quality-control data required by regulators, a process that delayed the original timeline.
23 Articles
23 Articles
Eli Lilly has once again secured significant results in late-stage clinical trials for its next-generation obesity treatment, 'Retatrutide.' By reconfirming a greater weight loss effect than existing GLP-1 class treatments, the likelihood of the drug establishing itself as a flagship product has increased. However, the application for U.S. approval, originally expected this year, has been postponed to early next year to supplement manufacturing …
Retatrutide Helped Adults With Diabetes or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds
The experimental drug retatrutide delivered another round of impressive weight loss and blood sugar management results, according to phase 3 clinical trials results shared by drugmaker Eli Lilly. The latest trials demonstrated weight loss of up to nearly 23 percent of starting body weight — positioning retatrutide as perhaps the most powerful weight loss drug yet developed for adults with heart disease or type 2 diabetes . The company said it pl…
Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year
After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
